Apex Fund Services Secures $30 Million Commitment from FTV Capital
First institutional financing to drive expansion through continued organic growth and acquisitions
Apex Fund Services (“Apex”), one of the world’s largest independent fund administration companies, today announced it had secured a $30 million commitment from FTV Capital for a minority interest in the Company. FTV Capital, the first institutional investor in Apex, is a growth equity investor with extensive experience and a global network in the financial services industry, and especially asset management.
Apex has 23 offices worldwide, including Singapore, Shanghai, Dubai and Switzerland, and delivers global fund administration solutions to investment managers investing in traditional and alternative assets. Apex offers clients a wide variety of specialized and integrated products supporting middle and back office fund administration, complex derivatives, risk reporting and corporate secretarial and fund formation administration, as well as specialist start up services to asset managers.
During 2010 Apex launched the world’s first real-time Middle Office (MOOR) service, giving investment managers immediate on the spot access to their portfolios. In addition, Apex offers a number of platforms giving clients a diverse range of fund launch options.
“Led by an exceptional management team, Apex has built one of the world’s fastest growing independent fund administration businesses through its innovative platform for emerging fund managers,” said Brad Bernstein, FTV Capital partner, head of the firm’s New York office, and new Apex board member. “Apex is unique in its ability to reach globally, service locally and provide cross-jurisdictional solutions and best practices; clients benefit significantly from the company’s deep expertise and a local presence that enables flexible, custom solutions.”
“This $30 million commitment will enable Apex to accelerate its model of delivering an increasing range of client service orientated products into the world’s major financial centres. Investment managers serviced by Apex have come to expect the highest level of client servicing available and this investment will help ensure these standards are maintained,” said Peter Hughes, Apex group managing director.
“We welcome the collaboration with FTV Capital, especially given FTV’s extensive Global Partner Network in the financial services industry. The Apex team has done a remarkable job building a highly successful business. In spite of challenging global economic conditions, assets under administration have doubled since 2008 and Apex is rapidly approaching the world’s top 25 fund administrators,” Hughes continued. “We remain committed to continuing the growth of the Company by entering attractive new markets and considering further strategic acquisitions. FTV’s capital, expertise, and network will help Apex with this strong growth trajectory as we open new offices in support of both the billion dollar fund market as well as emerging asset managers around the world who seek a proven fund administration partner.”
Apex service solutions are tailored to the investment managers' needs as well as the regulatory and investment environment within the main global financial centers. Apex administers both onshore and offshore investment funds such as mutual funds, UCITs, SICAVs, fund of funds, private equity, real estate, Shari'ah and partnerships from the firm’s global footprint of 23 offices around the world.
Apex Fund Services was advised by Frank Ennis of Katalyst Partners.
About Apex Fund Services
Apex Fund Services is one of the world’s largest independent fund administration companies. With nearly $20 billion of assets under administration and 200 employees in 23 offices across the globe, the Company’s growth is very much at the heart of Apex’s philosophy of providing personalized fund administration services by being based in the same location as its clients.
Apex provides the full suite of products and services, including fund set up, portfolio valuations, fund accounting, shareholder services, corporate secretarial administration, directorships and listing sponsorship. Apex offers a number of platforms including, Bermuda Emerging Manager platform (for small or start up funds), Luxembourg SIF platform, Luxembourg UCITS platform, Luxembourg Shari’ah platform (fully Shari’ah compliant) and the Malta PIF platform. For more information, please visit www.apexfundservices.com .
About FTV Capital
FTV Capital is a multi-stage growth equity firm that invests in high-growth companies offering a range of innovative solutions in business services, financial services, payments and transaction processing, and technology. FTV Capital provides entrepreneurs with unique access to its Global Partner Network, a group of the world’s foremost financial institutions that have invested in FTV Capital and its portfolio companies for more than a decade. Founded in 1998, FTV Capital has more than $1 billion across three funds, and has offices in San Francisco and New York. For more information, please visit www.ftvcapital.com .
Contact:
Apex Fund Services Limited
Peter Hughes, +44 7780 997609
Group
Managing Director
peter@apex.bm
Mark
Way, +44 7786 116991
Corporate Communication
mark@apexfunds.co.uk
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom